Evidence map›Paper›PMID 38410707›Full record

ArticleERJ open research2024

Prognostic factors of progressive fibrotic hypersensitivity pneumonitis: a large, retrospective, multicentre, observational cohort study.

Esteban Cano-Jiménez, Ana Villar Gómez, Eduardo Velez Segovia, Myriam Aburto Barrenechea, Jacobo Sellarés Torres, Joel Francesqui, Karina Portillo Carroz, Alan Jhunior Solis Solis, Orlando Acosta Fernández, Ana Belén Llanos González and 10 more

Open access · goldAbstract read
In one paragraph

Article in ERJ open research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Prognostic biomarkers for the development of progressive pulmonary fibrosis in hypersensitivity pneumonitis: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2025
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 12 institutions in 1 country.

Esteban Cano-JiménezHospital Universitario Lucus Augusti, Lugo, Spain.
Ana Villar GómezHospital Vall d'Hebrón, Barcelona, Spain.
Eduardo Velez SegoviaHospital Vall d'Hebrón, Barcelona, Spain.ORCID https://orcid.org/0000-0003-3215-9457
Myriam Aburto BarrenecheaHospital Universitario Galdakao, Galdakao, Spain.ORCID https://orcid.org/0000-0001-8644-1015
Jacobo Sellarés TorresCIBER de Respiratorio (CIBERES), Madrid, Spain.
Joel FrancesquiHospital Clínic, Barcelona, Spain.ORCID https://orcid.org/0000-0001-7106-3218
Karina Portillo CarrozHospital Universitari Germans Trias i Pujol, Barcelona, Spain.
Alan Jhunior Solis SolisHospital Universitari Germans Trias i Pujol, Barcelona, Spain.
Orlando Acosta FernándezComplejo Hospitalario Universitario de Canarias, Santa Cruz De Tenerife, Spain.
Ana Belén Llanos GonzálezComplejo Hospitalario Universitario de Canarias, Santa Cruz De Tenerife, Spain.ORCID https://orcid.org/0000-0002-0467-4024
Jaume Bordas-MartinezHospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain.ORCID https://orcid.org/0000-0003-4027-8907
Eva Cabrera CesarHospital Universitario Virgen de la Victoria, Málaga, Spain.
Eva Balcells VilarnauCIBER de Respiratorio (CIBERES), Madrid, Spain.
Diego Castillo VillegasCIBER de Respiratorio (CIBERES), Madrid, Spain.ORCID https://orcid.org/0000-0002-4862-3595
Ana Reyes PardessusHospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Coral González FernándezComplejo Hospitalario Universitario de Ourense, Ourense, Spain.
Marta García MoyanoHospital Universitario de Cruces, Barakaldo, Spain.
Amaia Urrutia GajateHospital Universitario de Cruces, Barakaldo, Spain.ORCID https://orcid.org/0000-0002-4088-4088
Andrés Blanco HortasFundación Instituto de Investigación Sanitaria de Santiago de Compostela, Hospital Universitario Lucus Augusti, Lugo, Spain.
María Molina-MolinaCIBER de Respiratorio (CIBERES), Madrid, Spain.
Centro de Investigación en Red en Enfermedades Cardiovasculares · ESBellvitge University Hospital · ESHospital de Cruces · ESHospital de Sant Pau · ESHospital Universitari Germans Trias i Pujol · ESHospital Universitario de Canarias · ESHospital Universitario Lucus Augusti · ESComplejo Hospitalario de Ourense · ESHospital Clínic de Barcelona · ESHospital Clínico Universitario Virgen de la Victoria · ESHospital de Galdakao · ESVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Fibrotic hypersensitivity pneumonitis (fHP) is an immune-mediated interstitial lung disease caused by sensitisation to chronic allergen inhalation. This study aimed to determine prognostic indicators of progression and mortality in fHP. Methods: This was a retrospective, multicentre, observational, cross-sectional cohort study of consecutive patients diagnosed with fHP from 1 January 2012 to 31 December 2021. Multivariate Cox regression analyses were used to calculate hazard ratios (HRs) with 95% confidence intervals for predictors of progression and survival. Results: A total of 403 patients were diagnosed with fHP: median (interquartile range) age 66.5 (14.0) years, 51.9% females and 55.1% never-smokers. The cause of fHP was mainly fungal (39.7%) or avian (41.4%). Lung biopsy was performed in 269 cases (66.7%). In the whole cohort the variables that were related to mortality or lung transplant were older age (HR 1.08; p<0.001), percentage predicted forced vital capacity (HR 0.96; p=0.001), lymphocytosis in bronchoalveolar lavage (BAL) (HR 0.93; p=0.001), presence of acute exacerbation during follow-up (HR 3.04; p=0.001) and GAP (gender, age and lung physiology) index (HR 1.96; p<0.01). In the group of biopsied patients, the presence of fibroblastic foci at biopsy (HR 8.39; p<0.001) stands out in multivariate Cox regression analyses as a highly significant predictor for increased mortality or lung transplant. GAP index (HR 1.26; p=0.009), lymphocytosis in BAL (HR 0.97; p=0.018) and age (HR 1.03; p=0.018) are also predictors of progression. Conclusions: The study identified several prognostic factors for progression and/or survival in fHP. The presence of fibroblastic foci at biopsy was a consistent predictor for increased mortality and the presence of lymphocytosis in BAL was inversely related to mortality.

Identifiers

PMID38410707
PMCPMC10895428
OpenAlexW4391845383

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.